Nurix Therapeutics (Nasdaq:NRIX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NRIX Overzicht aandelen

Nurix Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en op de markt brengen van kleine molecuul- en celtherapieën voor de behandeling van kanker, ontstekingsaandoeningen en andere ziekten.

Over het bedrijf

NRIX fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 29.13% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 1.6% per jaar dalen.

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Nurix Therapeutics, Inc. Concurrenten

BioCryst Pharmaceuticals

NasdaqGS:BCRX

US$1.5b

Bicycle Therapeutics

NasdaqGS:BCYC

US$1.6b

MannKind

NasdaqGM:MNKD

US$1.8b

Aurinia Pharmaceuticals

NasdaqGM:AUPH

US$1.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Nurix Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$21.67
52 Week Hoogtepunt	US$26.31
52 Week Laag	US$4.22
Bèta	2.22
11 maand verandering	-12.83%
3 maanden verandering	11.30%
1 Jaar Verandering	214.97%
33 jaar verandering	-24.63%
5 jaar verandering	n/a
Verandering sinds IPO	13.99%

Recent nieuws en updates

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Recent updates

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

Rendement voor aandeelhouders

	NRIX	US Biotechs	US Markt
7D	-6.6%	-1.6%	-0.7%
1Y	215.0%	17.6%	32.5%

Rendement versus industrie: NRIX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.

Rendement versus markt: NRIX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement	7.7%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: NRIX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van NRIX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	284	Arthur Sands	www.nurixtx.com

Nurix Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en op de markt brengen van kleine molecule- en celtherapieën voor de behandeling van kanker, ontstekingsaandoeningen en andere ziekten. Het bedrijf ontwikkelt NX-2127, een oraal biobeschikbare Bruton's tyrosinekinase (BTK) degrader voor de behandeling van recidief of refractaire B-cel maligniteiten; NX-5948, een oraal biobeschikbare BTK-afbreker voor de behandeling van recidief of refractair B-cel maligniteiten en auto-immuunziekten; en NX-1607, een oraal biobeschikbare Casitas B-lijn lymfoom proto-oncogen-B (CBL-B) remmer voor immuno-oncologische indicaties. Het ontwikkelt ook NX-0479/GS-6791, een IRAK4-afbreker voor de behandeling van reumatoïde artritis en andere ontstekingsziekten.

Nurix Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Nurix Therapeutics zich tot de beurswaarde?
NRIX fundamentele statistieken
Marktkapitalisatie	US$1.42b
Inkomsten(TTM)	-US$165.00m
Inkomsten(TTM)	US$62.30m

22.4x

P/S-verhouding

-8.5x

Koers/Winstverhouding

Is NRIX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NRIX resultatenrekening (TTM)
Inkomsten	US$62.30m
Kosten van inkomsten	US$196.50m
Brutowinst	-US$134.19m
Overige uitgaven	US$30.81m
Inkomsten	-US$165.00m

Laatst gerapporteerde inkomsten

May 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.56
Brutomarge	-215.39%
Nettowinstmarge	-264.84%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde NRIX op de lange termijn?

Bekijk historische prestaties en vergelijking

NRIX Overzicht aandelen

Beloningen

Risicoanalyse

Nurix Therapeutics, Inc. Concurrenten

NasdaqGS:BCRX

US$1.5b

NasdaqGS:BCYC

US$1.6b

NasdaqGM:MNKD

US$1.8b

NasdaqGM:AUPH

US$1.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Recent updates

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index